Evidence map›Paper›PMID 42446091›Full record

Trial reportFuture oncology (London, England)2026

Neoadjuvant nedaplatin and paclitaxel regimen with concurrent radiotherapy for esophageal squamous cell carcinoma: a single-arm phase II clinical trial.

Ting Liu, Xiao Dan, Qing Li, Peipei Wang, Yueyun Chen, Jiangfang Tian, Zhen Lin, Yang Hu, Huashan Shi, Zhenyu Ding

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ting LiuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.ORCID 0000-0002-2578-6789
Xiao DanDepartment of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qing LiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Peipei WangDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yueyun ChenDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jiangfang TianDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhen LinDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yang HuDepartment of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Huashan ShiDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhenyu DingDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.ORCID 0000-0002-9545-8844

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate the efficacy and safety of neoadjuvant concurrent chemoradiotherapy (CCRT) utilizing nedaplatin and paclitaxel in patients with locally advanced esophageal squamous cell carcinoma (ESCC). PATIENTS &

methodsLocally advanced ESCC patients received two cycles of nedaplatin plus paclitaxel or albumin-bound paclitaxel with concurrent radiotherapy (41.4-50.4 Gy) as neoadjuvant treatment. Immunohistochemical profiling was performed on biopsies and surgical specimens. The primary endpoint was the pathological complete response (pCR) rate.

resultsAmong 49 enrolled patients, 33 underwent surgery, yielding a pCR rate of 30.3%. Overall survival was inferior in resected patients with positive postoperative lymph nodes (HR 3.92, 95% CI 1.30-11.80,

conclusionNeoadjuvant nedaplatin and paclitaxel-based CCRT demonstrates encouraging preliminary antitumor efficacy. Tumor microenvironment profiling highlights FOXP3 and TIGIT dynamics as potential prognostic indicators. These hypothesis-generating insights warrant further validation in large-scale, randomized controlled trials. Clinical trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn), identifier is ChiCTR1900024628. Date of registration: 19 July 2019.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyAdultAgedFemaleForkhead Transcription FactorsHumansMaleMiddle AgedOrganoplatinum CompoundsPaclitaxelPathologic Complete ResponseTreatment OutcomeForkhead Transcription FactorsFOXP3 protein, humannedaplatinOrganoplatinum CompoundsPaclitaxelEsophageal squamous cell carcinoma (ESCC)immune checkpoints (ICs)nedaplatinneoadjuvant therapypathologic complete response (pCR)

Identifiers

PMID42446091
PMCPMC13432914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.